Abstract The progress of molecular genetics led to a revolution in prenatal diagnosis of inherited diseases, which also had affected the dermatology field profoundly. New molecular techniques have replaced fetal skin biopsies, which were previously used. Nowadays, we are standing on the brink of great changes, with the advent of noninvasive assays based on fetal cells and fetal DNA residing in the maternal blood. This review is aimed to give the dermatologist a current overview of the available methods for prenatal diagnosis, with an emphasis on genodermatoses.
Introduction
In the past, prenatal diagnosis for genodermatoses was complicated and risky, involving an invasive fetal skin biopsy (FSB). However, nowadays, with the advent of gene discovery, and with almost all genes responsible for the severe genodermatoses revealed, DNA-based prenatal diagnosis became a clinical-service reality [1] . Although invasive procedures are still necessary to acquire fetal cells, new noninvasive techniques are becoming available. These assays are based on fetal cells or fetal DNA in the maternal blood [2•] . This review was designed to provide a current overview of the available methods for prenatal diagnosis, with an emphasis on genodermatoses.
Fetal Skin Biopsy
In the past, FSB was the sole available method for prenatal diagnosis of genodermatoses and was mainly utilized for diagnosis of epidermolysis bullosa and ichthyoses [3] . In the beginning, a "blind" method was used to obtain fetal skin, with a very low efficiency and high rates of maternal and fetal injuries or infection [4] . Later, new techniques were developed, and FSB was performed with the aid of fetoscopy or ultrasonography [5] . This procedure was performed relatively late in pregnancy, between 15 and 22 weeks gestation [6] . The skin biopsy was analyzed with light and transmission electron microscopy, and later, with the development of specific antibodies, immunohistochemical tests were performed on the skin samples [6, 7] . Nowadays, FSB is hardly utilized, due to the introduction of newer molecular diagnostic procedures. FSB is an invasive method, prone to false-positive (due to mechanical trauma) and -negative (due to inadequate skin sampling) results [5] . Additionally, it has risk for fetal loss (1-3 %), amniotic fluid leakage, and fetal scarring [8] , and the number of centers with the experience and expertise to perform this technique is becoming increasingly low [9••] . At present, FSB is indicated in cases where insufficient DNA data are available, such as when the causative gene is unknown or the specific mutation could not be identified [9••, 10••] . FSB also might be useful in de novo cases, where there is a suspicion of a genodermatosis (such as epidermolysis bullosa with pyloric atresia) [11] .
procedure includes insertion of a needle through the skin and uterus into the amniotic cavity and aspiration of amniotic fluid, which contains fetal cells [13] . This procedure is usually performed around the 16 week of gestation and is usually guided by an ultrasound [13] . "Early" amniocentesis between gestation weeks 9 to 14 also can be performed, but it yields less amniotic fluid [14] .
Complications from this procedure include transient vaginal spotting or leakage of amniotic fluid (1-2 %) and rarely chorioamnionitis (<0.1 %). The rate of fetal loss has declined dramatically in recent years, and it is estimated that the excess fetal loss rate following this procedure is less than 0.2 % [15, 16] .
Chorionic Villus Sampling
In contrast to amniocentesis, which aspirates amniotic fluid, chorionic villus sampling (CVS) aspirates placental tissue [17] . This procedure was first reported in China [18] and was further developed in the Western world. Aspiration is performed under ultrasound guidance either in the percutaneous transabdominal or the transvaginal/transcervical approach [17] .
The major advantage of CVS on amniocentesis is the ability to perform this test early in pregnancy, and it has been performed successfully as early as 6 weeks gestation [17] . However, earlier reports suggested a higher rate of limb defects with lower gestational age [19, 20] , an association that was later refuted [21] . Nevertheless, most centers prefer to delay CVS until after the 10th week of gestation [17] . In addition to limb defects, CVS probably also bears a risk for fetal loss, which is comparable to second-trimester amniocentesis [22, 23•] .
Preimplantation Genetic Diagnosis
The field of preimplantation genetic screening and diagnosis is maybe one of the most rapidly advancing fields in medicine. Preimplantation genetic diagnosis (PGD) was developed to avoid the need for abortions, which in addition to the psychological and physiological effects on the mother [24] , often involves ethical issues [25] .
Since its introduction in 1990 [26] , PGD has become a wellestablished method for selecting embryos that are disease-free to be transferred to the uterus [27] . This method necessitates performing an in vitro fertilization cycle, which includes the use of exogenous hormones to stimulate ovaries to produce large number of follicles [28•, 29] . By follicular fluid aspiration, the oocytes residing inside these follicles are retrieved, and each oocyte is injected with a single spermatozoon. In order to perform PGD, three embryo biopsy techniques are available:
1. Polar body biopsy [30] : The polar body holds a complement of 23 maternal chromosomes, and therefore can be used for PGD of diseases inherited by the mother [31] . The main advantage of this method is the possibility to perform PGD even before fertilization, and thus helps to overcome legal restrictions on embryo biopsies that exist in several countries [32] . 2. Cleavage stage biopsy: This is the most commonly performed embryo biopsy method, which involves the removal of one or two blastomers from the embryo in the cleavage stage. In this embryonal stage, which usually occurs by the third day, the embryo has six to eight cells. Two major limitations of this technique are possible embryo damage leading to compromise in development and misdiagnosis due to cellular mosaicism. It has been estimated that the risk for mistakenly transferring an affected fetus is 2 % in autosomal recessive conditions and 11 % in autosomal dominant diseases [10••, 33] . 3. Trophectoderm biopsy [34] : trophectoderm is the outer cell mass of the embryo, which develops by the fifth day after fertilization and develops into the placenta [32] . This technique shows better results compared with the cleavage stage biopsy and therefore is expected to become more popular for PGD [35] .
A prominent technical hurdle in performing PGD is the small amount of DNA that is available for analysis in a single cell (6 pg). This obstacle can be overcome by performing nested or heminested PCR. Additionally, the high number of PCR cycles needed for single cell-PCR increases the risk for contamination, another limitation in this method [29] . Another difficulty is allele dropout, a condition in which only one of the alleles in a heterozygous sample amplifies [36] , which can lead to adverse misdiagnosis. Due to these difficulties, it is recommended that CVS or amniocentesis will be performed ultimately to confirm the genetic diagnosis [28•] . Other limitations include the high cost of the procedure and limited access, in addition to lower pregnancy rates [37] .
There are only a limited number of successful PGDs that have been performed for genodermatoses. PGD was performed for Herlitz junctional epidermolysis bullosa, and although pregnancy was not established in one case, an unaffected child was born in another family [38, 39] . PGD also was used for ectodermal dysplasia-skin fragility syndrome in two cases, resulting in delivery of a healthy child [40, 41] .
Noninvasive Prenatal Diagnosis
As explained above, all invasive methods for prenatal diagnosis carry some risk for the fetus and the mother. It is for this reason that noninvasive methods for prenatal diagnosis have emerged.
Fetal Cells in Maternal Blood
The fact that fetal cells are present in maternal blood has been known for more than 100 years [42] . These cells can be utilized as a source for the entire fetal genome, free of any confounding maternal genetic material [43] . Therefore, these cells can be especially valuable in analysis of diseases inherited in a Mendelian fashion, because it is possible to separate the maternal allele and the fetal allele from maternal origin [44] . The main challenge in this method is the ability to isolate the fetal cells from the maternal circulation, due to their very low concentrations in the maternal blood. It has been estimated that the number of fetal cells in maternal blood is 1 in 10 5 to 1 in 10 9 of mononuclear cells [45] . Additionally, the final purity of the fetal cells is low, and oftentimes they are contaminated with maternal cells [45] . Other obstacles include high levels of allele dropout and cellular apoptosis upon entrance to the maternal circulation [43] . However, maybe the greatest disadvantage with this method is the fact that fetal cells can exist in maternal circulation for years, and fetal cells were found in maternal circulation even after 27 years [46] . Therefore, new techniques involving cell-free fetal genetic material have been developed.
Cell-Free Fetal DNA and mRNA in Maternal Blood
The presence of fetal DNA in maternal blood was first discovered in 1997 by Lo et al. [47] , and fetal mRNA in maternal blood was described 3 years later [48] . The source of the fetal DNA is thought to be trophoblast cells that form the placenta, which undergo apoptosis and release nucleic acids [49] [50] [51] . Fetal DNA has been found to exist in concentrations of 3-6 % [52•]. The main advantage of fetal DNA compared with fetalcell based analysis is the fact that fetal DNA is cleared quickly after delivery, with a mean half-life of 16 minutes [53] . Another advantage is the fact that fetal DNA can be discovered in maternal blood as early as the fourth week of gestation, and reliably after the seventh week of gestation [54] . In addition to fetal DNA, fetal mRNA and microRNAs also exist in maternal plasma, and they can provide knowledge about fetal gene expression, mirroring different physiological conditions [48, [55] [56] [57] .
A major challenge when using fetal DNA for diagnosis is how to discriminate between the fetal and maternal DNA. Therefore, this approach is mostly useful for diagnosis of mutations that are inherited from the father and are absent in the mother's genome. To overcome this problem, an approach called the relative mutation dosage was developed [58, 59] . This method includes accurate quantification of the relative dosage of the mutant and wild-type alleles in plasma. Although this method has not been tested clinically
Ultrasonography

No family history
Maternal serum screening Fig. 1 A scheme summarizing the available prenatal diagnosis methods reviewed in the manuscript for genodermatoses, it has been utilized successfully for several inherited disorders, such as β-thalassemia and hemoglobin E disease [58] , and holds promise for the future.
Maternal Serum Screening
The maternal triple-marker screen is part of the standard clinical obstetric practice and is used routinely to diagnose Down syndrome, trisomy 18 , and open neural tube defects [60] . The most common cause for extremely low levels of unconjugated estradiol, one of the markers screened in the triple test, is X-linked ichthyosis. In this condition, there is placental insufficiency of steroid sulfatase, and therefore defective steroidogenesis [61] . In case maternal serum screening reveals isolated low levels of unconjugated estradiol, amniocentesis or CVS sampling must be performed to confirm the suspicion of X-linked ichthyosis [10••] .
Ultrasonography
Ultrasonography is a conventional method in prenatal diagnosis and is utilized commonly for this purpose. Hints for several genodermatoses can be obtained using this method, and this is especially valuable in de novo cases.
As already noted above, the presence of pyloric atresia may point at the possibility of epidermolysis bullosa, and other suggestive features may include ureteral stenosis, arthrogryposis, and nose or ear deformities [62] . Suspicion of Harlequin ichthyosis can arise based on facial dysmorphism, abnormal extremities, growth restriction, and hyperechogenic particles in the amniotic fluid [63, 64] . It has been advocated that facial dysmorphism can be displayed more clearly with the use of 3D ultrasound [65] . Other heritable skin conditions that can be detected by ultrasonography, based on their associated features, include hypohidrotic ectodermal dysplasia [66] , chondroectodermal dysplasia [67] , and Noonan syndrome [68] . For Noonan syndrome, it was actually shown that PTPN11 mutations are found in 11 % of fetuses with isolated cystic hygroma and in 2 % of fetuses with increased nuchal translucency [68] .
Another example for the use of ultrasonography in diagnosing genodermatoses is tuberous sclerosis, mostly based on the finding of cardiac rhabdomyomas. The presence of cardiac rhabdomyomas is the earliest and most commonly reported finding of tuberous sclerosis [69] . Although the association of a single cardiac rhabdomyoma with tuberous sclerosis is quite vague, the presence of multiple tumors should strongly raise the suspicion for this disease [69, 70] .
Ethical Considerations
The decision to perform a prenatal diagnosis is influenced by many factors, including religious, ethical, and intellectual values, and differ between different populations [71] .
Although the question what should be considered a severe phenotype for which prenatal diagnosis should be performed is universal and true to all genetic diseases, it seems to be more problematic when relating to skin diseases [72] . Although some genodermatoses are incompatible with life and lead to significant morbidity, such as Harlequin ichthyosis and some forms of epidermolysis bullosa, many other genodermatoses can result in cosmetic problems, with no effect on life expectancy. The development of PGD further complicates the ethical intricacy [73, 74] . It is believed that since there are no clear guidelines, each case should be carefully considered individually [72] .
Conclusions
Prenatal genetic testing for severe genetic skin diseases is now common practice in many centers in the world. This field is continuously evolving, and in the future noninvasive methods are believed to be easily available. The utilization of prenatal genetic diagnosis and PGD for skin disorders that can affect quality of life, but with milder phenotypes, poses a new challenge for health care providers, raising several complicated ethical issues. A scheme summarizing the available prenatal diagnosis methods is shown in Fig. 1 .
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